Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
暂无分享,去创建一个
Toshitaka Nakamura | H. Hagino | Masako Ito | H. Mizunuma | T. Nakano | Masato Tobinai | J. Hashimoto